stockportfolio.pro
Arvinas, Inc. (ARVN)
Healthcare · Biotechnology · NasdaqGS
Arvinas, Inc. revenue & earnings — last 9 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.58M | $14.32M | $43.00M | $25.90M | $53.60M | $131.40M | $78.50M | $263.40M | $262.60M |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Net income | $-24.05M | $-41.48M | $-70.30M | $-119.30M | $-191.00M | $-282.50M | $-367.30M | $-198.90M | $-80.80M |
| Net margin | -317.3% | -289.6% | -163.5% | -460.6% | -356.3% | -215.0% | -467.9% | -75.5% | -30.8% |
Source: Arvinas, Inc. SEC filings (10-K).
Explore 9 years of Arvinas, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ARVN in your portfolio →
Arvinas, Inc. financial history by metric
About Arvinas, Inc.
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Arvinas, Inc. — frequently asked questions
What is Arvinas, Inc.'s revenue?
Arvinas, Inc. (ARVN) reported revenue of $262.60M for fiscal year 2025, down 0.3% from the prior year, according to its SEC filings.
Is Arvinas, Inc. profitable?
No — ARVN reported a net loss of $-80.80M in fiscal 2025.
What is ARVN's P/E ratio?
Arvinas, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Arvinas, Inc. growing?
ARVN's revenue grew at roughly 58.9% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Arvinas, Inc. have?
As of fiscal year 2025, ARVN carried roughly $400,000 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Arvinas, Inc.'s market cap?
Arvinas, Inc. (ARVN) has a market capitalization of about $458.10M, based on the latest data in our nightly-refreshed cache.
When does Arvinas, Inc.'s fiscal year end?
ARVN's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Arvinas, Inc.'s official SEC filings (10-K and 10-Q), covering 9 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.